HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MoCRA Confidentiality For AE Reports? And Other Questions Raised At IBA Regulatory Forum

Executive Summary

Independent Beauty Association president and CEO Don Frey, Kerry Tassopoulos of Platt Cheema Richmond PLLC, and IBA board member and Co-CEO and president Craig Weiss of the Consumer Product Testing Company fielded questions on MoCRA implementation at IBA’s 2023 Technical/Regulatory Forum.

You may also be interested in...



MoCRA Check-In: FDA Guidance Urgently Needed As Year-End Compliance Deadlines Loom

John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.

NSF Leaders On How New Cosmetics Certification Could Bolster MoCRA Compliance

NSF’s Contents and Claims Certified Guideline for beauty and personal-care products should position companies well for compliance with new US regulations under the Modernization of Cosmetic Regulations Act, the organization says. NSF senior leaders discuss in an interview with HBW Insight.

Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act

Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel